Differentiation of the electrophysiological effects on the atrial myocardium between the pure Na channel blocker, pilsicainide, and flecainide

Cardiovasc Drugs Ther. 2004 Jul;18(4):295-303. doi: 10.1023/B:CARD.0000041249.35724.da.

Abstract

The purpose of this study was to identify the difference between the pure Na channel blocker, pilsicainide and Ic-antiarrhythmic drug, flecainide, on the atrial electrophysiological characteristics.

Methods: The subjects consisted of 24 patients (48 +/- 12 years-old: P-group) in whom pilsicainide was administrated intravenously (1 mg/kg/10 min) and 31 patients (47 +/- 15 years-old: F-group) in whom flecainide was administrated intravenously (2 mg/kg/10 min). The atrial effective refractory period (ERP-A), intra-atrial conduction time (CT), max intra-atrial conduction delay (Max CD), repetitive atrial firing zone (RAFZ), fragmented atrial activity zone (FAZ) and intra-atrial conduction delay zone (CDZ) were measured before and after the drugs.

Results: Pilsicainide and flecainide significantly prolonged the ERP-A (211 +/- 27 msec to 246 +/- 39 msec; p < 0.001, 217 +/- 25 msec to 244 +/- 33 msec; p < 0.001, respectively) and CT (121 +/- 33 msec to 149 +/- 43 msec; p < 0.001, 122 +/- 22 msec to 153 +/- 27 msec; p < 0.001, respectively) to the same degree. However, the Max CD was shortened by pilsicainide, but not by flecainide. The RAFZ, FAZ and CDZ decreased in the P-group (21 +/- 25 msec to 4 +/- 10 msec; p < 0.01, 24 +/- 24 msec to 14 +/- 18 msec; p < 0.05, 56 +/- 29 msec to 43 +/- 32 msec, p < 0.05, respectively), but not in the F-group.

Conclusions: The effects of atrial conduction delays may differ between pilsicainide and flecainide. Further examination will be needed to explain this mechanism.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Anti-Arrhythmia Agents / blood
  • Anti-Arrhythmia Agents / therapeutic use*
  • Atrial Flutter / drug therapy
  • Electrocardiography
  • Electrophysiologic Techniques, Cardiac
  • Female
  • Flecainide / blood
  • Flecainide / therapeutic use*
  • Heart Atria / drug effects*
  • Heart Atria / physiopathology
  • Heart Conduction System / drug effects
  • Heart Ventricles / drug effects
  • Humans
  • Lidocaine / analogs & derivatives*
  • Lidocaine / blood
  • Lidocaine / therapeutic use
  • Male
  • Middle Aged
  • Myocardium
  • Prospective Studies
  • Refractory Period, Electrophysiological / drug effects
  • Research Design
  • Sodium Channel Blockers / blood
  • Sodium Channel Blockers / therapeutic use*
  • Tachycardia, Atrioventricular Nodal Reentry / drug therapy
  • Tachycardia, Ventricular / drug therapy
  • Treatment Outcome
  • Wolff-Parkinson-White Syndrome / drug therapy

Substances

  • Anti-Arrhythmia Agents
  • Sodium Channel Blockers
  • Lidocaine
  • pilsicainide
  • Flecainide